New hope for aggressive brain cancer? trial combines novel drugs to fight recurrence.

NCT ID NCT07297212

Recruiting now Disease control Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 25, 2026 · Updated 19 times

Summary

This study tests a new drug called pumitamig, alone or with other medicines, in 75 adults whose glioblastoma (a severe brain cancer) has come back after standard treatment. The goal is to see if these combinations can shrink tumors and are safe. Participants must have had prior radiation and chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Affiliated Cancer Hospital of Shandong First Medical University
RECRUITING

Jinan, 250117, China
Affiliated Tumor Hospital of Chongqing Medical University
RECRUITING

Chongqing, 350209, China
Beijing Tiantan Hospital, Capital Medical University
RECRUITING

Beijing, 100070, China
Huashan Hospital, Fudan University
RECRUITING

Shanghai, 201107, China
Shenzhen Second People's Hospital
RECRUITING

Shenzhen, 518000, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, 430030, China

Conditions

Explore the condition pages connected to this study.

RECURRENT GLIOBLASTOMA